Duopharma Biotech Contributes to National Pharmaceutical Self-Reliance Through Manufacturing Capacity and Portfolio Growth
Duopharma Biotech Berhad held its 25th Annual General Meeting today, capping a successful FY2025 ended 31 December 2025, that saw the Company growing its revenue by 14.5% to RM931.69 million, from RM813.70 million in FY2024.